HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dietary Ingredient Advisory List Yet To Fulfill Potential For US FDA

Executive Summary

"We haven't utilized the ingredient advisory list quite as much as I'd like to see. But it's something we'll be working on this year,” says Cara Welch, acting director of FDA’s Office of Dietary Supplement Programs.

You may also be interested in...



US Rule For Mandatory Supplement Registration Would Likely Give FDA Authority For Fines

“We would certainly want to have some enforcement and be able to utilize that enforcement,” says ODSP acting director Cara Welch. Stakeholders opposed to the change should “get comfortable with the idea of opening up DSHEA and should most certainly be part of the discussion.”

Consumer Health Product Market Fraud During Pandemic Didn’t Surprise US FDA – Woodcock

“This type of activity always emerges during a crisis where people will take advantage of others’ desperation and fear,” says acting Commissioner Janet Woodcock in FDLI conference keynote. Regulated industries’ data are needed to continue responding to COVID-19 and prepare for “what comes next.”

Next US FDA Commissioner Will Have Opening To Fill In Dietary Supplement Programs Office

Steven Tave on 15 March will move from ODSP director to lead ORA’s Office of Strategic Planning and Operational Policy. Agency’s next commissioner, who Capitol Hill lobbyists say could be named next week, will appoint a replacement.

Related Content

Topics

UsernamePublicRestriction

Register

RS151561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel